358 related articles for article (PubMed ID: 17234366)
21. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence.
Otani K; Ujike H; Sakai A; Okahisa Y; Kotaka T; Inada T; Harano M; Komiyama T; Hori T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Neurosci Lett; 2008 Mar; 434(1):88-92. PubMed ID: 18280655
[TBL] [Abstract][Full Text] [Related]
22. Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT).
Peles E; Schreiber S; Adelson M
Eur Neuropsychopharmacol; 2008 Mar; 18(3):188-93. PubMed ID: 17997285
[TBL] [Abstract][Full Text] [Related]
23. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model.
King VL; Kidorf MS; Stoller KB; Schwartz R; Kolodner K; Brooner RK
J Subst Abuse Treat; 2006 Dec; 31(4):385-93. PubMed ID: 17084792
[TBL] [Abstract][Full Text] [Related]
24. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
25. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients.
Vigezzi P; Guglielmino L; Marzorati P; Silenzio R; De Chiara M; Corrado F; Cocchi L; Cozzolino E
J Subst Abuse Treat; 2006 Jul; 31(1):3-7. PubMed ID: 16814005
[TBL] [Abstract][Full Text] [Related]
26. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.
Rogers HL; Bhattaram A; Zineh I; Gobburu J; Mathis M; Laughren TP; Pacanowski M
J Clin Psychiatry; 2012 Sep; 73(9):1187-90. PubMed ID: 23059146
[TBL] [Abstract][Full Text] [Related]
27. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.
Shiran MR; Chowdry J; Rostami-Hodjegan A; Ellis SW; Lennard MS; Iqbal MZ; Lagundoye O; Seivewright N; Tucker GT
Br J Clin Pharmacol; 2003 Aug; 56(2):220-4. PubMed ID: 12895196
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
Brockmöller J; Meineke I; Kirchheiner J
Clin Pharmacol Ther; 2007 May; 81(5):699-707. PubMed ID: 17329996
[TBL] [Abstract][Full Text] [Related]
29. Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients.
Schreiber S; Peles E; Adelson M
Drug Alcohol Depend; 2008 Jan; 92(1-3):79-85. PubMed ID: 17706374
[TBL] [Abstract][Full Text] [Related]
30. CYP2D6 poor metabolizer genotype and smoking predict severe postoperative pain in female patients on arrival to the recovery room.
Yang Z; Yang Z; Arheart KL; Morris R; Zhang Y; Rodriguez Y; Song C; Gitlin MC; Candiotti KA
Pain Med; 2012 Apr; 13(4):604-9. PubMed ID: 22497725
[TBL] [Abstract][Full Text] [Related]
31. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype.
Chen SQ; Wedlund PJ
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):585-8. PubMed ID: 10678117
[TBL] [Abstract][Full Text] [Related]
32. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
33. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
[TBL] [Abstract][Full Text] [Related]
34. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption.
Candiotti KA; Yang Z; Rodriguez Y; Crescimone A; Sanchez GC; Takacs P; Medina C; Zhang Y; Liu H; Gitlin MC
Pain Med; 2009; 10(5):799-805. PubMed ID: 19523031
[TBL] [Abstract][Full Text] [Related]
35. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.
Peñas-Lledó EM; Dorado P; Agüera Z; Gratacós M; Estivill X; Fernández-Aranda F; Llerena A
Mol Psychiatry; 2011 Jul; 16(7):691-2. PubMed ID: 21321564
[No Abstract] [Full Text] [Related]
36. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
Maremmani I; Pani PP; Pacini M; Perugi G
J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
[TBL] [Abstract][Full Text] [Related]
37. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
[TBL] [Abstract][Full Text] [Related]
38. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
39. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
[TBL] [Abstract][Full Text] [Related]
40. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
